April 4, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Carbylan Therapeutics Inc (NASDAQ:CBYL) shares over potential securities laws violations by Carbylan Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Carbylan Therapeutics Inc (NASDAQ:CBYL) concerning whether a series of statements by Carbylan Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Carbylan Therapeutics Inc went public in early April 2015 and sold in its initial public stock offering 13 million shares of stock, raising $65.0 million in new capital.

Shares of Carbylan Therapeutics Inc (NASDAQ:CBYL) reached on June 8, 2015 as high as $9.22 per share.

However, since then, Carbylan Therapeutics stock declined to as low as $0.55 per share on March 24, 2016.